Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 2

The winners of the 2025 Milky Way Photographer of the Year contest have been announced, highlighting epic imagery of the Milky Way from around the world, and even from above it. The contest, hosted by travel photography blog Capture the Atlas, is in its eighth year.

This year, the contest received 6,000 entries from photographers of 16 different nationalities. Images spanned 25 locations around the globe, including Chile, the United States, Greece, Switzerland, Guatemala, New Zealand, Taiwan, Yemen, Chad, India, Namibia, Spain and more. Plus, an image taken from space was included in the collection for the first time. Some photos captured celestial events like a comet, a meteor shower and a lunar eclipse.

Dan Zafra, the editor of Capture the Atlas, curates the annual list based on image quality, the story behind the shot and the overall inspiration it provides. Zafra says the project’s goal is to inspire people to connect with the night sky and “to encourage photographers to explore and photograph the Milky Way from new angles.”

Read more | >

Vision is one of the most crucial human senses, yet over 300 million people worldwide are at risk of vision loss due to various retinal diseases. While recent advancements in retinal disease treatments have successfully slowed disease progression, no effective therapy has been developed to restore already lost vision-until now. KAIST researchers have successfully developed a novel drug to restore vision.

KAIST (represented by President Kwang Hyung Lee) announced on the 30th of March that a research team led by Professor Jin Woo Kim from the Department of Biological Sciences has developed a treatment method that restores vision through retinal nerve regeneration.

The research team successfully induced retinal regeneration and vision recovery in a disease-model mouse by administering a compound that blocks the PROX1 (prospero homeobox 1) protein, which suppresses retinal regeneration. Furthermore, the effect lasted for more than six months.

Read more | >

Science students and academics wrote papers about the mathematics and physics of Ringworld after it was published. Larry Niven discusses whether this would happen if Ringworld was published today.
–
Learn more ➤ https://www.newscientist.com/article/.…

Subscribe ➤ https://bit.ly/NSYTSUBS

Get more from New Scientist:
Official website: https://bit.ly/NSYTHP
Facebook: https://bit.ly/NSYTFB
Twitter: https://bit.ly/NSYTTW
Instagram: https://bit.ly/NSYTINSTA
LinkedIn: https://bit.ly/NSYTLIN

About New Scientist:
New Scientist was founded in 1956 for “all those interested in scientific discovery and its social consequences”. Today our website, videos, newsletters, app, podcast and print magazine cover the world’s most important, exciting and entertaining science news as well as asking the big-picture questions about life, the universe, and what it means to be human.

New Scientist.
https://www.newscientist.com/

Read more | >

A team of researchers at the University of California, Davis, made small tweaks to the molecular structure of lysergic acid diethylamide (LSD) to see if it could be turned into an effective brain-healing treatment for patients that suffer from conditions like schizophrenia — without risking a potentially disastrous acid trip.

As detailed in a new paper published in the journal Proceedings of the National Academy of Sciences last month, the researchers created a new compound called JRT by shifting the position of just two atoms of the psychedelic’s molecular structure.

With the two atoms flipped, the new drug could still stimulate brain cell growth and repair damaged neural connections, while simultaneously minimizing psychedelic effects, in mice.

Read more | >

Nitrous oxide, a commonly used analgesic gas, temporarily improved the opening of the blood-brain barrier (BBB) to allow gene therapy delivery in mouse models using focused ultrasound (FUS), UT Southwestern Medical Center researchers report in a new study. Their findings, published in Gene Therapy, could eventually lead to new ways to treat a variety of brain diseases and disorders.

“The approach we explored in this study has the potential to advance care for diseases of the brain that can be treated by targeted therapeutic delivery,” said study leader Bhavya R. Shah, M.D., Associate Professor of Radiology, Neurological Surgery, and in the Advanced Imaging Research Center at UT Southwestern. He’s also an Investigator in the Peter O’Donnell Jr. Brain Institute and a member of the Center for Alzheimer’s and Neurodegenerative Diseases. Deepshikha Bhardwaj, Ph.D., Senior Research Associate at UTSW, was the study’s first author.

The BBB is a highly selective border of semipermeable cells that line tiny blood vessels supplying blood to the brain. It is thought to have developed during evolution to protect the brain from toxins and infections in the blood. However, the BBB also impedes the delivery of drugs that could be used to treat neurologic or neuropsychiatric conditions, such as Alzheimer’s disease, multiple sclerosis, or brain tumors. Consequently, researchers have worked for decades to develop solutions that can temporarily open the BBB to allow treatments to enter.

Read more | >